Overexpression of SET is a Recurrent Event Associated with Poor Outcome and Contributes to Protein Phosphatase 2A Inhibition in Acute Myeloid Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2011 Dec 3

PMID 22133779

Citations 71

Authors

Ion Cristobal

Laura Garcia-Orti

Cristina Cirauqui

Xabier Cortes-Lavaud

Maria A Garcia-Sanchez

Maria J Calasanz

Maria D Odero

Affiliations

Soon will be listed here.

Abstract

Background: Protein phosphatase 2A is a novel potential therapeutic target in several types of chronic and acute leukemia, and its inhibition is a common event in acute myeloid leukemia. Upregulation of SET is essential to inhibit protein phosphatase 2A in chronic myeloid leukemia, but its importance in acute myeloid leukemia has not yet been explored.

Design And Methods: We quantified SET expression by real time reverse transcriptase polymerase chain reaction in 214 acute myeloid leukemia patients at diagnosis. Western blot was performed in acute myeloid leukemia cell lines and in 16 patients' samples. We studied the effect of SET using cell viability assays. Bioinformatics analysis of the SET promoter, chromatin immunoprecipitation, and luciferase assays were performed to evaluate the transcriptional regulation of SET.

Results: SET overexpression was found in 60/214 patients, for a prevalence of 28%. Patients with SET overexpression had worse overall survival (P<0.01) and event-free survival (P<0.01). Deregulation of SET was confirmed by western blot in both cell lines and patients' samples. Functional analysis showed that SET promotes proliferation, and restores cell viability after protein phosphatase 2A overexpression. We identified EVI1 overexpression as a mechanism involved in SET deregulation in acute myeloid leukemia cells.

Conclusions: These findings suggest that SET overexpression is a key mechanism in the inhibition of PP2A in acute myeloid leukemia, and that EVI1 overexpression contributes to the deregulation of SET. Furthermore, SET overexpression is associated with a poor outcome in acute myeloid leukemia, and it can be used to identify a subgroup of patients who could benefit from future treatments based on PP2A activators.

Citing Articles

Divergent Processing of Cell Stress Signals as the Basis of Cancer Progression: Licensing NFκB on Chromatin.

Vlahopoulos S Int J Mol Sci. 2024; 25(16).

PMID: 39201306 PMC: 11354898. DOI: 10.3390/ijms25168621.

Merkel Cell Polyomavirus targets SET/PP2A complex to promote cellular proliferation and migration.

Gupta P, Venuti A, Savoldy M, Harold A, Zito F, Taverniti V Virology. 2024; 597:110143.

PMID: 38917692 PMC: 11552451. DOI: 10.1016/j.virol.2024.110143.

Key chromatin regulator-related genes associated with the risk of coronary artery disease regulate the expression of HCFC1, RNF8, TNP1 and SET.

Bingyu W, Xi Y, Jiangfang L, Jianqing Z Heliyon. 2024; 10(7):e28685.

PMID: 38596069 PMC: 11002600. DOI: 10.1016/j.heliyon.2024.e28685.

Oncoprotein SET-associated transcription factor ZBTB11 triggers lung cancer metastasis.

Xu W, Yao H, Wu Z, Yan X, Jiao Z, Liu Y Nat Commun. 2024; 15(1):1362.

PMID: 38355937 PMC: 10867109. DOI: 10.1038/s41467-024-45585-5.

The next decade of SET: from an oncoprotein to beyond.

Yao H, Zhang M, Wang D J Mol Cell Biol. 2023; 16(1).

PMID: 38157418 PMC: 11267991. DOI: 10.1093/jmcb/mjad082.

References

Janssens V, Goris J, Van Hoof C . PP2A: the expected tumor suppressor. Curr Opin Genet Dev. 2005; 15(1):34-41. DOI: 10.1016/j.gde.2004.12.004. View

Kawabe T, Muslin A, Korsmeyer S . HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint. Nature. 1997; 385(6615):454-8. DOI: 10.1038/385454a0. View

Cristobal I, Garcia-Orti L, Cirauqui C, Alonso M, Calasanz M, Odero M . PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia. 2011; 25(4):606-14. DOI: 10.1038/leu.2010.294. View

Switzer C, Cheng R, Vitek T, Christensen D, Wink D, Vitek M . Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene. 2011; 30(22):2504-13. PMC: 3107340. DOI: 10.1038/onc.2010.622. View

Westermarck J, Hahn W . Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med. 2008; 14(4):152-60. DOI: 10.1016/j.molmed.2008.02.001. View

Trotta R, Ciarlariello D, Dal Col J, Allard 2nd J, Neviani P, Santhanam R . The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. J Exp Med. 2007; 204(10):2397-405. PMC: 2118465. DOI: 10.1084/jem.20070419. View

Janssens V, Goris J . Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001; 353(Pt 3):417-39. PMC: 1221586. DOI: 10.1042/0264-6021:3530417. View

Schonthal A . Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett. 2001; 170(1):1-13. DOI: 10.1016/s0304-3835(01)00561-4. View

Woodgett J, Damuni Z . Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. Biochem J. 1999; 341 ( Pt 2):293-8. PMC: 1220359. View

10.

Fathi A, Grant S, Karp J . Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev. 2010; 36(2):142-50. PMC: 2839044. DOI: 10.1016/j.ctrv.2009.12.004. View

11.

Li M, Makkinje A, Damuni Z . The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996; 271(19):11059-62. DOI: 10.1074/jbc.271.19.11059. View

12.

Neviani P, Santhanam R, Oaks J, Eiring A, Notari M, Blaser B . FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest. 2007; 117(9):2408-21. PMC: 1950458. DOI: 10.1172/JCI31095. View

13.

Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D . FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood. 2007; 111(1):275-84. PMC: 2200813. DOI: 10.1182/blood-2006-10-053884. View

14.

Seo S, McNamara P, Heo S, Turner A, Lane W, Chakravarti D . Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell. 2001; 104(1):119-30. DOI: 10.1016/s0092-8674(01)00196-9. View

15.

Farag S, Ruppert A, Mrozek K, Mayer R, Stone R, Carroll A . Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2004; 23(3):482-93. DOI: 10.1200/JCO.2005.06.090. View

16.

Harmala-Brasken A, Mikhailov A, Soderstrom T, Meinander A, Holmstrom T, Damuni Z . Type-2A protein phosphatase activity is required to maintain death receptor responsiveness. Oncogene. 2003; 22(48):7677-86. DOI: 10.1038/sj.onc.1207077. View

17.

Cristobal I, Blanco F, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J . SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2009; 115(3):615-25. DOI: 10.1182/blood-2009-06-227363. View

18.

Chao A, Tsai C, Wei P, Hsueh S, Chao A, Wang C . Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett. 2009; 291(1):99-107. DOI: 10.1016/j.canlet.2009.10.005. View

19.

Kandilci A, Mientjes E, Grosveld G . Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937. Leukemia. 2003; 18(2):337-40. DOI: 10.1038/sj.leu.2403227. View

20.

Ten Klooster J, Leeuwen I, Scheres N, Anthony E, Hordijk P . Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J. 2007; 26(2):336-45. PMC: 1783461. DOI: 10.1038/sj.emboj.7601518. View